ERBB3 and breast carcinoma: Pertuzumab, a humanized monoclonal antibody that also targets the NH2-terminal domain of ErbB2 and blocks the ErbB2 dimerization with ErbB3, is recently also accepted for a treatment of ErbB2 positive breast cancer in combination with chemotherapy.